<DOC>
	<DOC>NCT01671280</DOC>
	<brief_summary>To collect the efficacy and safety information of Azithromycin IV related to their appropriate use in daily practice</brief_summary>
	<brief_title>Drug Use Investigation Of Azithromycin IV For Community-Acquired Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pelvic Inflammatory Disease</mesh_term>
	<mesh_term>Pelvic Infection</mesh_term>
	<criteria>Male or Female patients who are prescribed Zithromac IV for communityacquired pneumonia or pelvic inflammatory disease. Subjects who have been prescribed Zithromac or ZithromacSR for communityacquired pneumonia or pelvic inflammatory disease.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>community-acquired pneumonia</keyword>
	<keyword>pelvic inflammatory disease</keyword>
	<keyword>Zithromax</keyword>
	<keyword>Zithromac</keyword>
	<keyword>Japanese</keyword>
	<keyword>Regulatory Post Marketing Commitment Plan</keyword>
</DOC>